
Suzhou MicroPort and Tinavi Medical Technologies entered into a letter of intent in relation to Tinavi’s potential acquisition of a controlling interest in Shanghai MicroPort Orthopedics.
Shanghai MicroPort Orthopedics possesses a line of joint replacement prostheses and established marketing channels developed over many years of serving overseas orthopedic markets, while Tinavi holds deep expertise and a leading position in the field of orthopedic surgical
robots. The business synergies, strategies, and long-term goals of both parties are highly aligned.
The potential transaction is in the planning stage and is subject to the successful conclusion of commercial negotiations on terms between the parties, the completion of due diligence, internal and regulatory approvals, etc. There is no assurance that the potential transaction will materialize or that the final terms will be as proposed.
Suzhou MicroPort and Tinavi Medical Technologies entered into a letter of intent in relation to Tinavi’s potential acquisition of a controlling interest in Shanghai MicroPort Orthopedics.
Shanghai MicroPort Orthopedics possesses a line of joint replacement prostheses and established marketing channels developed over many years of serving...
Suzhou MicroPort and Tinavi Medical Technologies entered into a letter of intent in relation to Tinavi’s potential acquisition of a controlling interest in Shanghai MicroPort Orthopedics.
Shanghai MicroPort Orthopedics possesses a line of joint replacement prostheses and established marketing channels developed over many years of serving overseas orthopedic markets, while Tinavi holds deep expertise and a leading position in the field of orthopedic surgical
robots. The business synergies, strategies, and long-term goals of both parties are highly aligned.
The potential transaction is in the planning stage and is subject to the successful conclusion of commercial negotiations on terms between the parties, the completion of due diligence, internal and regulatory approvals, etc. There is no assurance that the potential transaction will materialize or that the final terms will be as proposed.
Sources: MicroPort Scientific Corporation; Globe and Mail
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





